Abstract
The journey toward a cure for spinal cord injury (SCI) has taken many paths. In this article, we review these paths, and highlight the clinical applications of these experimental repair strategies. Initial strategies involved attempts at neuroprotection with steroids and other anti-inflammatory drugs. Other anti-ischemia treatments, agents to eliminate the damage from excitotoxicity, and anti-apoptotic agents were also tried. Another avenue involved enhancing the function of the remaining uninjured axons by measures to produce remyelination and medications to improve axonal conduction. In the last two decades there has been a major effort to enhance spinal cord axonal regeneration through a variety of techniques including neutralization of neurite inhibition, administration of neurotrophic factors, implantation of synthetic channels, and transplantation of a variety of cell types. Indeed, several of these strategies have been so promising in animals that clinicians have been stimulated to explore their potential human application. We also examine the different experimental models of SCI used to assess repair, and discuss how the injury model impacts on the assessment of axonal regeneration and functional recovery after SCI. The mechanisms of recovery that may be involved after SCI will be analyzed, and their relevance toward finding a cure for human SCI. Unfortunately, the goal of producing significant functional regeneration of the human spinal cord has not yet been achieved despite the many strategies that have been developed. It is our hope that improved understanding of the mechanisms underlying functional recovery will lead to successful therapeutic strategies in humans.
Keywords: repair, spinal cord injury, neuroprotection, regeneration, transplantation, synthetic channels, neurotrophic factors, mechanisms of recovery
Current Pharmaceutical Design
Title: Neuroprotection and Regeneration Strategies for Spinal Cord Repair
Volume: 11 Issue: 10
Author(s): Eve C. Tsai and Charles H. Tator
Affiliation:
Keywords: repair, spinal cord injury, neuroprotection, regeneration, transplantation, synthetic channels, neurotrophic factors, mechanisms of recovery
Abstract: The journey toward a cure for spinal cord injury (SCI) has taken many paths. In this article, we review these paths, and highlight the clinical applications of these experimental repair strategies. Initial strategies involved attempts at neuroprotection with steroids and other anti-inflammatory drugs. Other anti-ischemia treatments, agents to eliminate the damage from excitotoxicity, and anti-apoptotic agents were also tried. Another avenue involved enhancing the function of the remaining uninjured axons by measures to produce remyelination and medications to improve axonal conduction. In the last two decades there has been a major effort to enhance spinal cord axonal regeneration through a variety of techniques including neutralization of neurite inhibition, administration of neurotrophic factors, implantation of synthetic channels, and transplantation of a variety of cell types. Indeed, several of these strategies have been so promising in animals that clinicians have been stimulated to explore their potential human application. We also examine the different experimental models of SCI used to assess repair, and discuss how the injury model impacts on the assessment of axonal regeneration and functional recovery after SCI. The mechanisms of recovery that may be involved after SCI will be analyzed, and their relevance toward finding a cure for human SCI. Unfortunately, the goal of producing significant functional regeneration of the human spinal cord has not yet been achieved despite the many strategies that have been developed. It is our hope that improved understanding of the mechanisms underlying functional recovery will lead to successful therapeutic strategies in humans.
Export Options
About this article
Cite this article as:
Tsai C. Eve and Tator H. Charles, Neuroprotection and Regeneration Strategies for Spinal Cord Repair, Current Pharmaceutical Design 2005; 11 (10) . https://dx.doi.org/10.2174/1381612053507404
DOI https://dx.doi.org/10.2174/1381612053507404 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Expression and Functions of Galectin-1 in Sensory and Motoneurons
Current Drug Targets TRP Channels in the Digestive System
Current Pharmaceutical Biotechnology Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry Ewing’s Sarcoma Cancer Stem Cell Targeted Therapy
Current Stem Cell Research & Therapy Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy
CNS & Neurological Disorders - Drug Targets Conference Report [IANR V and 9th GCNN Conference with 4th ISCITT Symposium]
CNS & Neurological Disorders - Drug Targets The Protective Effects of Levosimendan on Ischemia/Reperfusion Injury and Apoptosis
Recent Patents on Cardiovascular Drug Discovery Peripheral and Central Mechanisms of Mechanical Allodynia: Neurokinin Receptor for Therapeutic Target
Central Nervous System Agents in Medicinal Chemistry Synthesis and Preliminary Biochemical Evaluation of Novel Derivatives of PCP
Letters in Drug Design & Discovery Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis
Current Medicinal Chemistry Regenerative Therapies in Cartilage and Bone: Current Patents, Technologies, and Emerging Applications
Recent Patents on Regenerative Medicine Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry Rationale for Development of New Oral Anticoagulants
Cardiovascular & Hematological Disorders-Drug Targets Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology